

Aline S C Fabricio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7254368/publications.pdf>

Version: 2024-02-01

48
papers

979
citations

516561

16
h-index

454834

30
g-index

49
all docs

49
docs citations

49
times ranked

1657
citing authors

#	ARTICLE	IF	CITATIONS
1	To which extent are per-and poly-fluorinated substances associated to metabolic syndrome?. Reviews on Environmental Health, 2022, 37, 211-228.	1.1	4
2	Perfluoroalkyl substances and thyroid stimulating hormone levels in a highly exposed population in the Veneto Region. Environmental Research, 2022, 203, 111794.	3.7	7
3	Biological variation and reference change value as decision criteria in clinical use of tumor biomarkers. Are they really useful?. Clinical Chemistry and Laboratory Medicine, 2022, 60, e136-e137.	1.4	2
4	Associations of Perfluoroalkyl Substances with Prevalence of Metabolic Syndrome in Highly Exposed Young Adult Community Residentsâ€™A Cross-Sectional Study in Veneto Region, Italy. International Journal of Environmental Research and Public Health, 2021, 18, 1194.	1.2	18
5	The association between perfluoroalkyl substances and lipid profile in exposed pregnant women in the Veneto region, Italy. Ecotoxicology and Environmental Safety, 2021, 209, 111805.	2.9	12
6	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. Oral Oncology, 2021, 114, 105128.	0.8	11
7	Phenomapping of Patients with Primary Breast Cancer Using Machine Learning-Based Unsupervised Cluster Analysis. Journal of Personalized Medicine, 2021, 11, 272.	1.1	9
8	Associations between perfluoroalkyl substances and lipid profile in a highly exposed young adult population in the Veneto Region. Environment International, 2020, 145, 106117.	4.8	52
9	DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3â€™-End Usage. Cancers, 2020, 12, 1453.	1.7	18
10	State of the art and trends of circulating cancer biomarkers. International Journal of Biological Markers, 2020, 35, 12-15.	0.7	9
11	ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancerâ€™patients undergoing therapy with trastuzumab. Scientific Reports, 2020, 10, 3016.	1.6	14
12	Serum Tumor Markers in Paraneoplastic Neurologic Syndromes: A Systematic Review of Guidelines. Frontiers in Neurology, 2020, 11, 607553.	1.1	2
13	Insufficient uptake of systematic search methods in oncological clinical practice guideline: a systematic review. BMC Medical Research Methodology, 2019, 19, 180.	1.4	4
14	Shed HER2 surrogacy evaluation in primary breast cancer patients: a study assessing tumor tissue HER2 expression at both extracellular and intracellular levels. Scandinavian Journal of Clinical and Laboratory Investigation, 2019, 79, 260-267.	0.6	4
15	Preanalytical stability of [-2]proPSA in whole blood stored at room temperature before separation of serum and plasma: implications to Phi determination. Clinical Chemistry and Laboratory Medicine, 2019, 57, 521-531.	1.4	5
16	Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial. Pharmacological Research, 2018, 132, 72-79.	3.1	104
17	Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. BMC Cancer, 2018, 18, 651.	1.1	16
18	Indicators of inappropriate tumour marker use through the mining of electronic health records. Journal of Evaluation in Clinical Practice, 2017, 23, 895-902.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Epidemiology-Based Assessment of Tumor Marker Overordering in Breast Cancer: An Algorithm to Examine Different Disease Conditions. <i>International Journal of Biological Markers</i> , 2017, 32, 471-473.	0.7	2
20	Circulating Tumor Markers: A Guide to Their Appropriate Clinical Use: <i>Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 2)</i>. <i>International Journal of Biological Markers</i> , 2017, 32, 1-52.	0.7	13
21	Circulating Tumor Markers: A Guide to their Appropriate Clinical Use. <i>International Journal of Biological Markers</i> , 2017, 32, 147-181.	0.7	12
22	Appropriateness of tumor marker request: a case of study. <i>Annals of Translational Medicine</i> , 2017, 5, 274-274.	0.7	6
23	Markers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases. , 2017, , 33-45.		0
24	Circulating Tumor Markers: A Guide to their Appropriate Clinical use: Comparative Summary of Recommendations from Clinical Practice Guidelines (PART 1). <i>International Journal of Biological Markers</i> , 2016, 31, 332-367.	0.7	18
25	An epidemiology-based model as a tool to monitor the outbreak of inappropriateness in tumor marker requests: a national scale study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 473-82.	1.4	19
26	Sirtuin 1 stabilization by HuR represses TNF- α - and glucose-induced E-selectin release and endothelial cell adhesiveness<i>in Vitro</i>: relevance to human metabolic syndrome. <i>Clinical Science</i> , 2014, 127, 449-461.	1.8	35
27	An epidemiology-based model to estimate the rate of inappropriateness of tumor marker requests. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 889-97.	1.4	7
28	Evaluation of a sex hormone-binding globulin automated chemiluminescent assay. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2013, 73, 480-484.	0.6	2
29	Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 1815-24.	1.4	32
30	Inflammation Markers: New Actors in the Cancer Biomarker Tale. <i>International Journal of Biological Markers</i> , 2013, 28, 1-2.	0.7	0
31	Human Amniotic Fluid Stem Cell Preconditioning Improves Their Regenerative Potential. <i>Stem Cells and Development</i> , 2012, 21, 1911-1923.	1.1	112
32	Interplay Between miR-155, AT1R A1166C Polymorphism, and AT1R Expression in Young Untreated Hypertensives. <i>American Journal of Hypertension</i> , 2011, 24, 241-246.	1.0	135
33	New Frontiers in Tumor Marker Studies: From Biobanking to Collaboration in Translational Research. <i>International Journal of Biological Markers</i> , 2011, 26, 73-74.	0.7	7
34	Development of a Website and Biobank Database for the Nanosized Cancer Polymarker Biochip Project: A Multicenter Italian Experience. <i>International Journal of Biological Markers</i> , 2011, 26, 197-206.	0.7	2
35	Circulating Sex Hormones and Tumor Characteristics in Postmenopausal Breast Cancer Patients. A Cross-Sectional Study. <i>International Journal of Biological Markers</i> , 2011, 26, 241-246.	0.7	8
36	Cyclooxygenase-independent mechanism of ibuprofen-induced antipyresis: the role of central vasopressin V1 receptors. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 670-681.	1.0	8

#	ARTICLE	IF	CITATIONS
37	The antipyretic effect of dipyron is unrelated to inhibition of PGE ₂ synthesis in the hypothalamus. <i>British Journal of Pharmacology</i> , 2011, 162, 1401-1409.	2.7	32
38	Osteopontin, asbestos exposure and pleural plaques: a cross-sectional study. <i>BMC Public Health</i> , 2011, 11, 220.	1.2	5
39	Testosterone and Biological Characteristics of Breast Cancers in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 2942-2948.	1.1	21
40	Evaluation of cell-free DNA in urine as a marker for bladder cancer diagnosis. <i>International Journal of Biological Markers</i> , 2009, 24, 147-155.	0.7	20
41	Hydroxyurea induces vasopressin release and cytokine gene expression in the rat hypothalamus. <i>Journal of Neuroimmunology</i> , 2006, 179, 94-100.	1.1	2
42	Central endothelin ETB receptors mediate IL-1-dependent fever induced by preformed pyrogenic factor and corticotropin-releasing factor in the rat. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 290, R164-R171.	0.9	30
43	Interleukin-1 mediates endothelin-1-induced fever and prostaglandin production in the preoptic area of rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2006, 290, R1515-R1523.	0.9	22
44	Endothelin-1 as a central mediator of LPS-induced fever in rats. <i>Brain Research</i> , 2005, 1066, 92-100.	1.1	37
45	Mirtazapine acutely inhibits basal and K ⁺ -stimulated release of corticotropin-releasing hormone from the rat hypothalamus via a non-genomic mechanism. <i>Psychopharmacology</i> , 2005, 178, 78-82.	1.5	13
46	The effects of selective and nonselective cyclooxygenase inhibitors on endothelin-1-induced fever in rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2005, 288, R671-R677.	0.9	31
47	Essential role for endothelin ETB receptors in fever induced by LPS (E. coli) in rats. <i>British Journal of Pharmacology</i> , 1998, 125, 542-548.	2.7	48
48	Use of Routine Health Datasets to Assess the Appropriateness of Diagnostic Tests in the Follow-Up of Breast Cancer Patients: A Population-Based Study on 3930 Patients. <i>Risk Management and Healthcare Policy</i> , 0, Volume 15, 1087-1100.	1.2	2